18-SEP-2025 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3743 257 152 88 34 3 02/06/2019 444 185
Screened at PD     1319 91 68 45 16 2      
Pre-Screened prior to PD     2414 156 74 39 17 1      
Treatment-naive     10 10 10 4 1 0      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     513 32 14 8 4 0      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     1972 237 216 67 22 3      
Screened at PD     1093 108 99 46 17 2      
Pre-Screened prior to PD     814 116 104 17 4 1      
Treatment-naive     10 10 10 4 1 0      
After PD on a Lung_MAP Sub-Study     55 3 3 0 0 0      
 
Sub-Study Assignments (open studies only)
S1800E     195 195 195 59 18 3      
S1900G     32 9 4 2 1 0      
S1900J     13 13 3 1 1 0      
S1900K     22 16 14 5 2 0      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     535 48 40 27 15 3      
Initial sub-study registrations     523 48 40 27 15 3      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 24 24 24 22 13 2 05/22/2025 316 96
Docetaxel plus Ramucirumab Y   12 12 12 11 6 0      
Cemiplimab plus Docetaxel and Ramucirumab Y   12 12 12 11 7 2      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 21 7 4 1 0 0 05/05/2023 288 105
Capmatinib + Osimertinib + Ramucirumab Y   11 4 3 1 0 0      
Capmatinib + Osimertinib Y   10 3 1 0 0 0      
S1900J: MET Amplification: Amivantamab Hyaluronidase   88 2 2 1 0 0 0 11/19/2024 197 75
Amivantamab Hyaluronidase Y   2 2 1 0 0 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 14 13 11 4 2 1 08/08/2024 268 91
Tepotinib + Ramucirumab Y   9 9 7 2 1 1      
Tepotinib Y   5 4 4 2 1 0